<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In recent pediatric trials of <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), children with <z:e sem="disease" ids="C0013080" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Down syndrome</z:e> (DS) have had significantly more megakaryoblastic <z:hpo ids='HP_0001909'>leukemia</z:hpo> and have experienced better outcome than other children </plain></SENT>
<SENT sid="1" pm="."><plain>To further characterize <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> in DS, Children's <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Group Studies 2861 and 2891 prospectively studied demography, biology, and response in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) of children with and without DS </plain></SENT>
<SENT sid="2" pm="."><plain>These studies evaluated timing of induction therapy and compared postremission chemotherapy with marrow transplantation in 1,206 children </plain></SENT>
<SENT sid="3" pm="."><plain>One-hundred eighteen (9.8%) had DS, a fourfold increase in 20 years </plain></SENT>
<SENT sid="4" pm="."><plain>DS patients were younger, had lower white blood cell and platelet counts, more antecedent <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, <z:hpo ids='HP_0011009'>acute</z:hpo> megakaryoblastic <z:hpo ids='HP_0001909'>leukemia</z:hpo> or undifferentiated <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, and an under-representation of chromosomal translocations (P &lt; .001 for each variable) </plain></SENT>
<SENT sid="5" pm="."><plain>Four-year event-free survival in DS was 69% versus 35% in others (P &lt; .001) </plain></SENT>
<SENT sid="6" pm="."><plain>Intensively timed induction conferred significantly higher mortality in DS patients; bone marrow transplantation offered no advantage </plain></SENT>
<SENT sid="7" pm="."><plain>Conventional induction followed by chemotherapy achieved an 88%, 4-year, disease-free survival in DS patients versus 42% in others (P &lt; .001) </plain></SENT>
<SENT sid="8" pm="."><plain>Megakaryoblastic <z:hpo ids='HP_0001909'>leukemia</z:hpo> was unfavorable in others but prognostically neutral in DS </plain></SENT>
<SENT sid="9" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> in DS is demographically and biologically distinct from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> in other children </plain></SENT>
<SENT sid="10" pm="."><plain>It is singularly responsive to conventional chemotherapy and may warrant even less therapy </plain></SENT>
<SENT sid="11" pm="."><plain>The increasing proportion of DS patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> most likely reflects changes in attitudes about entering DS patients on <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> trials and possibly increasing ability to distinguish megakaryoblastic <z:hpo ids='HP_0001909'>leukemia</z:hpo> from <z:hpo ids='HP_0005526'>lymphoid leukemia</z:hpo> </plain></SENT>
</text></document>